These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 35339102)
1. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Rosebraugh M; Stodtmann S; Liu W; Facheris MF Parkinsonism Relat Disord; 2022 Apr; 97():68-72. PubMed ID: 35339102 [TBL] [Abstract][Full Text] [Related]
2. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Savaryn JP; Smith RL; Rosebraugh M; Neenan M; Burton R; Marsh K; Wagner D Pharmacol Res Perspect; 2024 Apr; 12(2):e1190. PubMed ID: 38597598 [TBL] [Abstract][Full Text] [Related]
3. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. Rosebraugh M; Liu W; Neenan M; Facheris MF J Parkinsons Dis; 2021; 11(4):1695-1702. PubMed ID: 34366380 [TBL] [Abstract][Full Text] [Related]
7. Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants. Rosebraugh M; Neenan M; Facheris M Clin Pharmacol Drug Dev; 2023 Apr; 12(4):407-415. PubMed ID: 36394144 [TBL] [Abstract][Full Text] [Related]
8. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Bergquist F; Ehrnebo M; Nyholm D; Johansson A; Lundin F; Odin P; Svenningsson P; Hansson F; Bring L; Eriksson E; Dizdar N Neurology; 2022 Sep; 99(10):e965-e976. PubMed ID: 35705502 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Othman AA; Dutta S Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449 [TBL] [Abstract][Full Text] [Related]
12. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334 [TBL] [Abstract][Full Text] [Related]
14. Current and novel infusion therapies for patients with Parkinson's disease. Antonini A; D'Onofrio V; Guerra A J Neural Transm (Vienna); 2023 Nov; 130(11):1349-1358. PubMed ID: 37672049 [TBL] [Abstract][Full Text] [Related]
15. Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. Rosebraugh M; Kalluri HV; Liu W; Locke C; Sidhu D; Han JH; Benesh J Pharmacol Res Perspect; 2019 Apr; 7(2):e00473. PubMed ID: 30977301 [TBL] [Abstract][Full Text] [Related]